CancerDrs

Breast Cancer clinical trials in Wisconsin

19 actively recruiting breast cancer trials at 52 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Wisconsin:
  • Langlade Hospital and Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
  • Aurora Saint Luke's South Shore — Cudahy, Wisconsin
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Wisconsin:
  • Research Site — Madison, Wisconsin
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Wisconsin:
  • Aurora BayCare Medical Center — Green Bay, Wisconsin
  • Aurora St Lukes Medical Center — Milwaukee, Wisconsin
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Wisconsin:
  • Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
  • Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
Phase 2 Recruiting Industry

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other

Study of 18F-FFNP Breast PET/MRI

This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT06086704
Sites in Wisconsin:
  • UW Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT05216432
Sites in Wisconsin:
  • UW Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in Wisconsin:
  • Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
EARLY Phase 1 Recruiting Academic/Other

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regula…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT04174352
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
  • Wisconsin Oncology Network (WONIX) sites — Madison, Wisconsin
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin:
  • Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Wisconsin:
  • Massive Bio SYNERGY-AI site — Milwaukee, Wisconsin
NA Recruiting Academic/Other

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).

Sponsor: Medical College of Wisconsin
NCT ID: NCT03824145
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 4 Recruiting Academic/Other

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be init…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT03096418
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
NA Recruiting Academic/Other

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT06295744
Sites in Wisconsin:
  • UW Carbone Cancer Center — Madison, Wisconsin
NA Recruiting Academic/Other

WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial Participation for Rural and Low Income Women

This clinical trial tests how well the Women's Engagement for Cancer Awareness, Resources, and Education (WE-CARE) community health forums work to increase breast cancer screening and clinical trial participation for rural and low income w…

Sponsor: Mayo Clinic
NCT ID: NCT07644702
Sites in Wisconsin:
  • Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
NA Recruiting Academic/Other

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical act…

Sponsor: Medical College of Wisconsin
NCT ID: NCT07227077
Sites in Wisconsin:
  • Froedtert Hospital — Milwaukee, Wisconsin

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07